Year None2022202120202019 Jul 29, 2022 FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Indi Jul 11, 2022 Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflu Jul 05, 2022 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 06, 2022 Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0. Jun 03, 2022 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 25, 2022 Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatmen May 05, 2022 Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update May 05, 2022 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 06, 2022 Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Next page next › Last page last » Displaying 19 - 27 of 36
